Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are pleased to welcome a new group leader to Ludwig Oxford: Dr. Chunxiao Song. Chunxiao has joined us as a Ludwig Assistant Member and his group will be based in the Target Discovery Institute. His research focus is chemical epigenetics. He joins us from Stanford University, where he was a post-doctoral researcher in Stephen Quake's group.

A headshot profile photo of Chunxiao SongChunxiao applies a mix of chemical biology, biophysics and genomics approaches to analyze the epigenome. As a graduate student at the University of Chicago, he developed a technology that permits profiling of epigenetic modifications on a single molecule of DNA, and a series of chemical labeling techniques to dissect the functional roles of epigenetic marks. The latter have become standard methods in the field. Song himself applied them to profile the distribution of two types of epigenetic marks across the mouse genome. As a post-doctoral researcher, he devised a highly sensitive method to visualize two major types of DNA modification on a single molecule of DNA.

His laboratory at the Ludwig Institute for Cancer Research, Oxford will continue to develop novel tools and technologies to explore the mechanisms, regulation and interplay of epigenetic modifications made to chromatin, DNA and RNA—the transcribed genetic information. He also plans to develop new technologies to analyze the epigenome in individual cells and apply them to study the heterogeneity of cells within tumors. Such studies promise to open a new window into the biology of tumor evolution and could provide valuable clues to cancer prevention.

Chunxiao's laboratory will also conduct applied research, developing new tools to capture molecules of DNA shed by tumor cells into bodily fluids. He hopes to use these tools to develop new epigenetic biomarkers for liquid biopsies. These minimally invasive biopsies have the potential to significantly improve the early detection of cancers, the personalization of cancer therapy and the clinical monitoring of patient prognoses and responses to treatment.